INMI Lazzaro Spallanzani IRCCS

What INMI Lazzaro Spallanzani IRCCS does

INMI Lazzaro Spallanzani IRCCS is a public Italian research hospital (Istituto di Ricovero e Cura a Carattere Scientifico) founded in 1936 and headquartered in Rome, specializing in infectious diseases, tropical medicine, and global health. It operates within Italy's Servizio Sanitario Nazionale under the oversight of the Ministry of Health and Regione Lazio, serving as the national reference center for bioterrorism preparedness, SARS, viral hemorrhagic fevers, and other high-consequence pathogens. The institution employs between 501 and 1,000 staff under the leadership of General Director Cristina Matranga, Scientific Director Enrico Girardi, Administrative Director Barbara Solinas, and Healthcare Director Andrea Antinori, and coordinates the SERESMI regional surveillance system for Lazio.

The hospital's operational assets include 152 inpatient beds, 6 day-hospital beds, Italy's only Biosafety Level 4 laboratory, and a biobank holding approximately 1,255,000 biological samples affiliated with the BBMRI-ERIC European research infrastructure. Its technology and product portfolio spans advanced molecular diagnostics (including a patented INMI Tuberculosis Test), whole-genome sequencing, next-generation sequencing platforms, HIV pre-exposure prophylaxis programs (including a long-acting Cabotegravir pilot launched in January 2025), and a Center for Permanent Healthcare Training. The institution coordinates the National Antimicrobial Stewardship Network from 2026, participates in the EU reference laboratory consortium EURL-PH-ERZV, and contributes to WHO clinical guidelines. Five researchers are listed in the Stanford/Elsevier Top 2% Scientists ranking.

The institution's business model is primarily public-sector: clinical revenues flow from Italian SSN reimbursements (DRG-based and per-capita allocations from Regione Lazio), while research operations are funded through competitive public grants from the EU (Horizon Europe, ECDC), the Italian Ministry of Health (Ricerca Corrente and Ricerca Finalizzata), and other public agencies. The institution is currently expanding physical infrastructure through the Polo dei Laboratori Rita Levi Montalcini (inaugurated October 2025), a Casa Spallanzani guesthouse (opening March 2026), and a joint infected-patient surgical unit with San Camillo Hospital (launched November 2025).

Name

INMI Lazzaro Spallanzani IRCCS

Legal name

Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani IRCCS

Website

https://inmi.it

Company type

Private

Founded year

1936

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Public Italian research hospital in Rome specializing in infectious diseases and tropical medicine, operating within the Italian National Health Service. Houses Italy's only BSL-4 laboratory and a 1.25 million-sample biobank, serving as national reference center for bioterrorism preparedness and high-consequence pathogens.

Ownership category

akta.pro rank

Product category

Infectious Disease Hospital Services

NAICS

General Medical and Surgical Hospitals (622110), Medical Laboratories (621511), All Other Outpatient Care Centers (621498)

SIC

Services-Hospitals (8060), Services-Medical Laboratories (8071), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Inpatient Infectious Disease & Isolation Specialty Hospitals (HLAFAHAI)

akta.pro secondary industries

General Infectious Disease (HLAKAGAA), Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC), Disease-Specific Reference Laboratory Networks (e.g., TB, HIV, Influenza) (HLAJAIAD), Data Integration, Interoperability & Reporting (ELR/HIE/CDC/NNDSS) (HLAJABAN), Infectious Disease POCT (Respiratory, STI, HIV, Sepsis) (HLAHAOAA)

Keywords

• Infectious disease treatment
• Clinical research services
• Hospital care services
• Public health surveillance
• Diagnostic laboratory services

Headquarters

HQ city

Rome

HQ country

Italy

HQ region

Europe

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

1. National Health Service (SSN) Reimbursement: As a public IRCCS, the institute operates primarily through the Italian National Health Service (Servizio Sanitario Nazionale). Patients access services with NHS prescriptions (impegnative), with ticket fees for standard consultations. The regional government (Regione Lazio) funds operational costs and research activities.
2. Private Professional Services (ALPI): The institute offers private pay consultations and services outside the NHS system, priced according to specialist fees. These are booked through ALPI (Attività Libero Professionale Intramoenia) via email or CUP.
3. 5x1000 Tax Donation Funding: Italian taxpayers can designate 5x1000 of their tax return to the institute for public research support. Funds are allocated through competitive internal grants to young researchers under 45 years old for clinical and translational research projects.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels5 records

Core offering

INMI Lazzaro Spallanzani IRCCS is a public research hospital that delivers specialized clinical care for infectious diseases (HIV/AIDS, viral hepatitis, tuberculosis, COVID-19, tropical and emerging infections) across 152 inpatient beds, day hospital, and 20+ outpatient clinics. It simultaneously operates advanced diagnostic and research laboratories (including Italy's only BSL-4 facility and five BSL-3 labs), conducts translational and clinical research programs, runs a biobank of 1.255 million samples, and serves as Italy's national reference center for bioterrorism, SARS, and hemorrhagic fevers, plus a European reference laboratory for emerging viral pathogens.

Product overview

INMI Lazzaro Spallanzani IRCCS is Italy's leading infectious disease research hospital comprising clinical care services (inpatient hospitalization, day hospital, and 20+ specialized outpatient clinics), advanced diagnostic laboratories (virology, BSL4 high-containment, imaging), translational and clinical research programs (HIV, COVID-19, hepatitis, tuberculosis, antimicrobial resistance, emerging infections), and healthcare professional training. The institute operates as a unified platform combining patient care, scientific research, and education, with key services including the CRAIDS AIDS Reference Center, PrEP clinics, tropical medicine, pregnancy infections, and specialized surgery for infected patients.

Differentiator

Problem solved

Functional benefit

Products and services

• Ricovero e Day Hospital (Inpatient and Day Hospital Services) Inpatient hospitalization and day hospital services with 152 active beds for adult acute infectious disease patients, 6 day hospital beds, intensive care unit, and hospice for end-of-life palliative care. Available through NHS referral.
• Ambulatorio CRAIDS (Regional AIDS Reference Center - Stanza 13) Regional AIDS Reference Center offering free and anonymous HIV testing, rapid tests for HIV and syphilis, screening for sexually transmitted infections, PrEP and PEP counselling, and patient intake for HIV care.
• Ambulatorio PrEP (Pre-Exposure Prophylaxis Clinic) Pre-exposure prophylaxis clinic providing oral and injectable long-acting cabotegravir PrEP for HIV prevention, targeting individuals at risk through sexual transmission.
• Ambulatorio Monoclonali (Monoclonal Antibody Therapy Clinic) Early therapy outpatient clinic providing monoclonal antibodies or antiviral drugs for symptomatic COVID-19 patients in early stages who are at high risk of severe disease progression.
• Ambulatorio Malattie Tropicali e Medicina dei Viaggi (Tropical Disease and Travel Medicine Clinic) Specialized tropical disease and travel medicine clinic offering diagnosis of imported infections, vaccination for yellow fever and other travel-related diseases, and rare disease management including leprosy, Whipple's disease, Lyme disease, and Chagas disease.
• Ambulatorio Malattie Infettive della Gravidanza (Infections in Pregnancy Clinic) Center for prevention and care of infections in pregnancy, offering preconception counselling, prenatal screening, management of infectious complications during pregnancy, and prevention of vertical transmission for HIV and hepatitis.
• Diagnostica per Immagini (Medical Imaging) Medical imaging department providing traditional radiology, multislice CT, 1.5T MRI, ultrasound, bone densitometry (DEXA/MOC), with particular focus on infectious diseases, transplant diagnostics, and radiation dose optimization.
• Laboratorio di Virologia (Virology Reference Laboratory) Virology laboratory designated as one of four European reference laboratories for emerging, rodent-borne, and zoonotic viral pathogens (EURL-PH-ERZV), providing advanced molecular diagnostics, genome sequencing, and hantavirus detection including Andes strain protocols.
• Laboratorio BSL4 (Biosafety Level 4 High-Containment Laboratory) Italy's only biosafety level 4 laboratory for handling the most dangerous pathogens, part of the high-containment facility connected to the new Polo dei Laboratori Rita Levi Montalcini.
• Ricerca Traslazionale (Translational Research Unit) Translational research unit developing new diagnostic and therapeutic approaches for infectious diseases, including the patented INMI test for tuberculosis that distinguishes active replication from latent infection, and autophagy studies for M. tuberculosis clearance.
• Network Antimicrobial Stewardship (National Antimicrobial Stewardship Research Network) National research network coordinated by Spallanzani together with ISS and five Italian IRCCS institutions, aimed at promoting responsible antibiotic use and developing intervention models for antimicrobial resistance.
• SERESMI (Regional Service for Epidemiology, Surveillance and Control of Infectious Diseases) Regional Service for Epidemiology, Surveillance and Control of Infectious Diseases managing surveillance systems, epidemiological data analysis, outbreak response coordination, and public health interventions for the Lazio region.
• Centro di Formazione Permanente in Sanità (Permanent Healthcare Training Center) Permanent training center for healthcare professionals established in March 2024, providing ECM-certified courses, the regional Talent Management program, Family and Community Nurse training, and biosafety courses.
• Chirurgia del Paziente Infetto (Surgery for Infected Patients) Specialized surgical unit for infected patients opened November 2025 with two operating theaters, dedicated to managing post-surgical infections, orthopedic prosthesis complications, abdominal and thoracic conditions requiring preoperative antibiotic therapy.

Quantifiable outcome

• 90 years of continuous infectious disease service with national/international recognition
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability7 records

Feature3 records

Partnerships

14 partnerships are on record, tiered core and minor.

• Istituto Superiore di Sanità (ISS)coreStrategic or Co-development PartnerCollaborative partnership in the national antimicrobial resistance network 'Network collaborativo a carattere nazionale per la realizzazione di un modello clinico-gestionale per l'ottimizzazione dell'uso dei farmaci antimicrobici (Antimicrobial Stewardship)'. The network, funded by the Ministry of Health, aims to develop shared models for appropriate antibiotic use across Italy's reference infectious disease centers.
• IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico di MilanocoreStrategic or Co-development PartnerPartner in the national antimicrobial stewardship research network, contributing to the development of shared models for appropriate antibiotic use.
• Azienda Ospedaliero-Universitaria Policlinico Sant'Orsola-Malpighi di BolognacoreStrategic or Co-development PartnerPartner in the national antimicrobial stewardship research network, contributing clinical and research expertise to appropriate antibiotic use models.
• Fondazione Policlinico Universitario Agostino Gemelli di RomacoreStrategic or Co-development PartnerPartner in the national antimicrobial stewardship research network, providing clinical research collaboration for antibiotic stewardship.
• ISMETT di PalermocoreStrategic or Co-development PartnerPartner in the national antimicrobial stewardship research network, contributing Mediterranean perspective to antimicrobial resistance initiatives.
• Ospedale Sacro Cuore Don Calabria di Negrar, VeronacoreStrategic or Co-development PartnerPartner in the national antimicrobial stewardship research network, contributing to appropriate antibiotic use research across Italian regions.
• Ospedale Pediatrico Bambino GesùcoreStrategic or Co-development PartnerJoint research collaboration on Long COVID treatment with antibody therapy. The study, published in The Lancet Infectious Diseases, combined Spallanzani's infectious disease expertise with Bambino Gesù's pediatric immunology capabilities. Researchers from both institutions identified immunological biomarkers and mechanisms underlying treatment response.
• Azienda Ospedaliera San Camillo-ForlaninicoreStrategic or Co-development PartnerLong-standing collaboration through Polo Ospedaliero Interaziendale Trapianti (POIT) for pancreas, liver, and kidney transplants. Expanded in 2025 with new 'Surgery for the Infected Patient' unit, integrating Spallanzani's infectious disease expertise with San Camillo's surgical capabilities. Two operating theaters dedicated to infected patient surgery established at Spallanzani.
• Comune di RomaminorGTM or Marketing PartnerCollaboration during European Testing Week for free HIV/STI testing events in partnership with Farmacap at municipal offices.
• ECDC - European Centre for Disease Prevention and ControlcoreStrategic or Co-development PartnerActive participation in European public health response networks. The Virology Laboratory operates within the EURL-PH-ERZV (EU reference laboratory consortium for emerging, rodent-borne and zoonotic viral pathogens), one of four European reference labs together with Sweden, Hungary, and Institut Pasteur Paris.
• Public Health Agency of SwedencoreStrategic or Co-development PartnerOne of four European reference laboratories in the EURL-PH-ERZV consortium for emerging, rodent-borne and zoonotic viral pathogens.
• National Biosafety Laboratory HungarycoreStrategic or Co-development PartnerOne of four European reference laboratories in the EURL-PH-ERZV consortium for emerging, rodent-borne and zoonotic viral pathogens.
• Institut Pasteur, PariscoreStrategic or Co-development PartnerOne of four European reference laboratories in the EURL-PH-ERZV consortium for emerging, rodent-borne and zoonotic viral pathogens.
• Life Sciences CompaniesminorStrategic or Co-development PartnerIndustrial partners registered in the 'Albo dei Partner Industriali' for joint research projects, technology transfer, spin-off development, and innovation activities. Companies must be regularly established with proven technological and scientific competencies in life sciences.

Scale indicators8 records

Recent moves4 records

Expansion highlights5 records

Direct peers

• Public Health Agency of Sweden (Folkhälsomyndigheten): Swedish national public health agency and another EURL-PH-ERZV partner reference laboratory. Comparable as a national-level infectious disease reference center coordinating surveillance and reference diagnostics.
• Bernhard Nocht Institute for Tropical Medicine: German tropical and infectious disease reference center with BSL-4 capability. Comparable as a European specialty infectious disease research hospital with high-containment laboratory operations.
• Istituto Superiore di Sanità (ISS): Italian national health research and reference institute. Direct peer and active AMR network partner with overlapping infectious disease reference and surveillance mandates within Italy.
• Institut Pasteur: Paris-based infectious disease research institute and one of Spallanzani's three EURL-PH-ERZV partner reference laboratories. Directly comparable as a national infectious disease reference center combining research, surveillance, and high-containment labs.
• Robert Koch Institute: Germany's federal infectious disease reference center. Closely comparable as a public-sector infectious disease reference institute combining surveillance, high-containment research, and clinical guidance.

Regional players

• Ospedale Pediatrico Bambino Gesù: Italian pediatric research hospital and active Long COVID research collaborator with Spallanzani. Comparable as an Italian public IRCCS with research-driven specialty care, though pediatric-focused.
• Fondazione Policlinico Universitario Agostino Gemelli: Major Italian Catholic university hospital and AMR network partner with Spallanzani. Comparable as a large Italian research hospital with overlapping infectious disease research programs.
• IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico di Milano: Italian IRCCS research hospital and AMR network partner. Comparable as an Italian public research hospital with translational research and infectious disease activity.

Broad incumbents

• Charité – Universitätsmedizin Berlin: One of Europe's largest university hospitals with significant infectious disease departments. Comparable as a public-sector integrated research hospital, though broader across specialties than Spallanzani's infectious disease focus.
• Karolinska Institutet: Sweden's leading medical university with extensive infectious disease research. Comparable as a public-sector infectious disease research powerhouse, though broader in scope than Spallanzani's specialty focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/INMISpallanzani
• YouTubeyoutube.com/channel/UC8q2Yn6mV6nV6OnG2ddqZFQ
• Facebookfacebook.com/INMISpallanzani
• LinkedInlinkedin.com/company/irccs-instituto-nazionale-malattie-infettive-l.-spallanzani-

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about INMI Lazzaro Spallanzani IRCCS